Frontline Corp. (532042)
Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹61.54 |
| Market Cap | ₹33.32 Cr |
| P/E Ratio | 5.79 |
| ROCE | 4.73% |
| ROE | 17.89% |
| Dividend Yield | 0% |
| Profit Growth | -35.21% |
| Debt/Equity | — |
| Sales Growth | 10.34% |
| 52-Week Range | ₹25.05 — ₹61.54 |
| Sector | Transport Services |
| Book Value | ₹30 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Frontline Corp is a small road-transport player with a market cap of just ₹33 crore. Mr. Market has put a low P/E of 5.79 on it, but I have learned that a low multiple is only interesting when the business deserves it. This is a commodity-like industry with no pricing power and no obvious moat; anyone with a truck can compete. The numbers tell a mixed, rather worrying story. Sales are growing at 10.34%, and ROE is 17.89%, but ROCE is only 4.73%. That large gap between return on equity and return on capital is a warning flag: the equity return is likely being magnified by leverage, not by superior operations. Latest quarter net profit is ₹0 crore, and profit growth is down 35.21%. The Piotroski F-Score of 4 out of 9 reinforces my caution — financial health is weak. There is no dividend, so as a minority shareholder I receive no cash while waiting for value. Book value is ₹30, yet the shares trade at ₹61.54, at the top of the 52-week range, so I am not being offered a margin of safety on assets. The PEG ratio of 0.56 looks enticing, but it is based on falling earnings; a value trap is still cheap. In Buffett's words, it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. This looks like a cyclical, leveraged transporter enjoying the tailwind of higher sales but failing to convert it into profit. I would wait for evidence of durable margins and debt comfort before acting.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer